As markets tumble further into deep and muddy terrain, many of us are getting increasingly anxious about what to do with our capital. I asked Wayne Himelsein, who has a long track record of outperforming, why he is buying Eli Lilly and Merck.
As markets tumble further into deep and muddy terrain, many of us are getting increasingly anxious about what to do with our capital. I asked Wayne Himelsein, who has a long track record of outperforming, why he is buying Eli Lilly and Merck.
Share this Article
Recommended